Диссертация (1174220), страница 45
Текст из файла (страница 45)
– 11. - Р. 1789-1796.187222. Lehmann-Horn K., Penkert H., Grein P. et al. PML during dimethyl fumarate treatment ofmultiple sclerosis: How does lymphopenia matter? // Neurology. – 2016. - 87(4). - Р. 440-441.223. Lily O., McFadden E., Hensor E. et al. Disease-specific quality of life in multiple sclerosis: theeffect of disease modifying treatment. // Mult Scler. – 2006. - 12(6). - Р. 808–813.224. Linker R.A., Haghikia A. Dimethyl fumarate in multiple sclerosis: latest developments, evidenceand place in therapy. // Ther Adv Chronic Dis – 2016. - 7(4). - Р. 198-207.225.
Lobentanz I.S., Asenbaum S., Vass K. et al. Factors influencing quality of life in multiplesclerosis patients: disability, depressive mood, fatigue and sleep quality. // Acta Neur Scand –2004. - 110(1). - Р. 6–13.226. Lundmark F., Duvefelt K., Iacobaeus E. et al. Variation in interleukin 7 receptor alpha chain(IL7R) influences risk of multiple sclerosis.
// Nat. Genet. – 2007. – 39. - Р. 1108-1113.227. Lysandropoulos A.P., Havrdova E. ParadigMS Group. 'Hidden' factors influencing quality of lifein patients with multiple sclerosis. Eur J Neurol. – 2015. - 22 Suppl 2. - Р. 28-33.228. Maghzi A.H., Ghazavi H., Ahsan M. et al. Increasing female preponderance of multiple sclerosisin Isfahan, Iran: a population-based study. // Multiple Sclerosis. – 2010. -16(3). - Р. 359–361.229. Major E.
Progressive multifocal luekoencephalopathy in patients on immunomodulatorytherapies. // Annu Rev Med – 2010. – 61. - Р. 35–47.230. Mamutse G., Woolmore J., Pye E. et al. Vitamin D receptor gene polymorphism is associatedwith reduced disability in multiple sclerosis. // Mult Scler. – 2008. – 14. - Р. 1280-1283.231. Mansiaux Y., Carrat F. Contribution of Genome-Wide Association Studies to ScientificResearch: A bibliometric survey of the citation impacts of GWAS and candidate gene studiespublished during the same period and in the same journals. // PLoS One – 2012. – 7. - e51408.232. Martinez-Martin P.
What is quality of life and how do we measure it? Relevance to Parkinson'sdisease and movement disorders. // Mov Disord. – 2017. - 32(3). - Р. 382-392.233. Maruszczak M.J., Montgomery S.M., Griffiths M.J. et al. Cost–utility of fingolimod comparedwith dimethyl fumarate in highly active relapsing–remitting multiple sclerosis (RRMS) inEngland. // J Med Econ – 2015. – 18. - Р. 874–885.234. Matute-Blanch C., Montalban X., Comabella M. Multiple sclerosis, and other demyelinating andautoimmune inflammatory diseases of the central nervous system. // Handb Clin Neurol.
– 2017.– 146. - Р. 67-84.235. McCullagh R., Fitzgerald A.P., Murphy R.P., Cooke G. Long-term benefits of exercising onquality of life and fatigue in multiple sclerosis patients with mild disability: a pilot study. // ClinRehabil. – 2008. - 22(3). - Р. 206-214.188236. McDonald W.I., Compston A., Edan G. et al. Recommended diagnostic criteria for multiplesclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. // AnnNeurol.
– 2001. – 50. - Р. 121–127.237. McGuigan C., Dunne C., Crowley J. et al. Population frequency of HLA haplotypes contributesto the prevalence difference of multiple sclerosis in Ireland. // J Neurol. – 2005. – 252. - Р. 1245–1248.238.
McHorney C.A., Ware J.E. Jr., Raczek A.E. The MOS 36-Item Short-Form Health Survey (SF36): II. Psychometric and clinical tests of validity in measuring physical and mental healthconstructs. // Med Care. – 1993. - 31(3). - Р. 247-263.239. Mechelli R., Annibali V., Ristori G. et al. Multiple sclerosis etiology: beyond genes andenvironment. // Expert Rev Clin Immunol.
– 2010. – 6. - Р. 481-490.240. Mehling M., Kappos L., Derfuss T. Fingolimod for multiple sclerosis: mechanism of action,clinical outcomes, and future directions. // Curr Neurol Neurosci Rep. – 2011. - 11(5). - Р. 492497.241. Melendez-Torres G.J., Auguste P., Armoiry X. et al. Clinical effectiveness and costeffectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematicreview and economic evaluation. // Health Technol Assess. – 2017. - 21(52). - Р.
1-352.242. Meletiche D.M., Lofland J.H., Young W.B. Quality-of-life differences between patients withepisodic and transformed migraine. Headache. – 2001. – 41. - Р. 573–8.243. MelisM.,BiagiC.,SmåbrekkeL.etal.Drug-InducedProgressiveMultifocalLeukoencephalopathy: A Comprehensive Analysis of the WHO Adverse Drug ReactionDatabase. // CNS Drugs. – 2015. - 29(10). - Р.
879-891.244. Merrill J., Hanak S., Pu S., et al. Teriflunimide reduces behavioral, electrophysiological andhistopathological deficits in the dark agouti rat model of experimental autoimmuneencephalomyelitis. // J Neurol – 2009. – 256. - Р. 89–103.245. Mikol D.D., Barkhof F., Chang P.
et al. Comparison of subcutaneous interferon beta-1a withglatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetatein Relapsing MS Disease (REGARD) study): a multicentre, randomised, parallel, open-labeltrial. // Lancet Neurol. – 2008. - 7(10).
- Р. 903-914.246. Miller A.E., O'Connor P., Wolinsky J.S. et al. Pre-specified subgroup analyses of a placebocontrolled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. // MultScler. – 2012. – 18. - Р. 1625-1632.247. Mitchell A.J., Benito-León J., González J.M.M., Rivera-Navarro J. Quality of life and itsassessment in multiple sclerosis: integrating physical and psychological components ofwellbeing. // Lancet Neurology.
– 2005. - 4(9). - Р. 556–566.189248. Montalban X., Comi G., O'Connor P. et al. Oral fingolimod (FTY720) in relapsing multiplesclerosis: impact on health-related quality of life in a phase II study. // Mult Scler. – 2011. 17(11). - Р. 1341-1350.249. Montalban X., Hauser S.L., Kappos L. et al. Ocrelizumab versus placebo in primary progressivemultiple sclerosis. // N Engl J Med. – 2017. - 376(3). - Р. 209-220.250. Mosca L., Mantero V., Penco S. et al.
HLA-DRB1*15 association with multiple sclerosis isconfirmed in a multigenerational Italian family. // Funct Neurol. – 2017. - 32(2). - Р. 83-88.251. Motl R.W., Gosney J.L. Effect of exercise training on quality of life in multiple sclerosis: ameta-analysis. // Mult Scler. – 2008. - 14(1). - Р. 129-135.252. Motsinger A.A., Brassat D., Caillier S.J. et al.
Complex gene–gene interactions in multiplesclerosis: a multifactorial approach reveals associations with inflammatory genes. //Neurogenetics. – 2007. – 8. - Р. 11–20.253. Moutsianas L., Jostins L., Beecham A.H. et al. Class II HLA interactions modulate genetic riskfor multiple sclerosis. // Nat Genet. – 2015. - 47(10). - Р. 1107-1113.254. Multiple Sclerosis International Federation. // Atlas of MS. - 2013.255. Myers J.A., McPherson K.M., Taylor W.J.. et al.
Duration of condition is unrelated to healthstate valuation on the EuroQoL. // Clin Rehabil. – 2003. - 17(2). - Р. 209-215.256. National Clinical Guideline Centre (UK). Multiple Sclerosis: Management of Multiple Sclerosisin Primary and Secondary Care. // London: National Institute for Health and Care Excellence(UK). - 2014 Oct. – Р. 120.257. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal2013.NationalinstituteforHealthandCareExcellence,2013,https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technologyappraisal2013-pdf-2007975843781258. NICE Citizens Council.
Quality Adjusted Life Years (QALYs) and the Severity of Illness. //London: National Institute for Health and Care Excellence (NICE). – 2008. - (2). - Р. 1-50.259. Nicoletti A., Messina S., Bruno E. et al. Risk factors in multiple sclerosis: a population-basedcase-control study in Sicily. Background and methods. // Neurol Sci. – 2016. - 37(12). - Р. 19311937.260. Nielsen N.M., Harpsøe M., Simonsen J. et al.
Age at Menarche and Risk of Multiple Sclerosis: AProspective Cohort Study Based on the Danish National Birth Cohort. // Am J Epidemiol. –2017. - 185(8). - Р. 712-719.261. Noble J.G., Osborne L.A., Jones K.H. et al. Commentary on ‗disability outcome measures inmultiple sclerosis clinical trials‘ // Multiple Sclerosis. – 2012. - 18(12). - Р.
1718–1720.190262. Nortvedt M.W., Riise T., Frugård J., et al. Prevalence of bladder, bowel and sexual problemsamong multiple sclerosis patients two to five years after diagnosis. // Mult Scler. – 2007. - 13(1).- Р. 106-112.263. Nortvedt M.W., Riise T., Myhr K.M., Nyland H.I. Quality of life as a predictor for change indisability in MS. // Neurology. – 2000. - 55(1).
- Р. 51–54.264. Noserworthy J., Miller D., Compston A. Disease-modifying treatments in multiple sclerosis. //In: McAlpine‘s Multiple sclerosis. 4th edition. Ed. By A.Compaston et al. Churchill Livingstone,Elsevier. – 2006. - Р. 729-802.265. O‘Brien B. Multiple sclerosis: Series on health. // London: Office of Health Economics, 1987.266. O‘Connor P., Li D, Freedman M.S. et al.: A Phase II study of the safety and efficacy ofteriflunomide in multiple sclerosis with relapses. // Neurology. – 2006. – 66.
- Р. 894-900.267. O‘Connor P., Wolinsky J., Confavreux C., et al. Randomized trial of oral teriflunomide forrelapsing multiple sclerosis. // N Engl J Med. – 2011. – 365. - Р. 1293–1303.268. O‘Gorman C., Lucas R., Taylor B. Environmental Risk Factors for Multiple Sclerosis: A Reviewwith a Focus on Molecular Mechanisms. // Int J Mol Sci. – 2012. - 13(9). - Р. 11718–11752.269. Okuda D.T., Srinivasan R., Oksenberg J.R., et al. Genotype-Phenotype correlations in multiplesclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRImeasures. // Brain.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
